Can-Fite BioPharma Ltd. (NYSE American: CANF) reported clinical data from its Phase 2a study of namodenoson in patients with advanced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE